Abstract
Hepatocyte growth factor (HGF) is expressed in placental syncitium and fetal organs and acts as a mitogen, motogen, and morphogen in vitro, suggesting a role in fetal growth and development. We aimed to examine the correlates of serum HGF in human cord blood. HGF was measured by ELISA using recombinant human HGF and mouse MAb to recombinant human HGF (Immunology Institute, Tokyo). Umbilical vein blood was collected prospectively at 148 deliveries including 94 normal pregnancies and 54 pregnancies complicated by medical conditions, primarily diabetes mellitus and pregnancy-induced hypertension. Growth parameters, gestation, pregnancy history, and perinatal events were recorded. Sera from 54 adolescents and 32 adult controls were also analyzed. Cord HGF [0.97 (0.66-1.33) ng/mL] [median (25-75 percentile)] was higher than HGF levels in adolescent sera [0.28 (0.21-0.35) ng/mL, p< 0.0001] and adult control sera [0.23 (0.14-0.31) ng/mL, p < 0.0001]. Cord HGF correlated with gestational age (r = 0.42,p = 0.0001) in normal pregnancies, with term babies (n = 69) having higher cord HGF than babies less than 37 wk of gestation(n = 25) [1.11 (0.78-1.45), 0.78 (0.46-1.03) ng/mL, p = 0.0007]. However, there was no relationship between gestation and cord HGF in complicated pregnancies. Cord HGF did not differ at term between appropriate for gestational age babies and small for gestational age babies. There were no independent correlations between cord HGF and birth weight, birth length and placental weight. We provide evidence for the first time that cord HGF levels are high and relate to gestation in normal pregnancies. HGF may have a significant role in fetal development during pregnancy.
Similar content being viewed by others
Main
HGF was cloned in 1989(1) and is so named because of its potent mitogenic action on hepatocytes. It is also a mitogen to epithelial and endothelial cells and is synthesized by mesenchymal cells(2), thus implicating a potential role in epithelial-mesenchymal interactions(3). HGF is identical to scatter factor and lung fibroblast-derived growth factor which was isolated from an embryonic lung fibroblast cell line(4). The ability of cells to scatter in response to HGF in vitro may indicate a role in vivo in cell migration and tissue morphogenesis(5, 6). HGF mRNA and its protein are present in placental mesenchymal cells and amniotic epithelium of the placenta(7). HGF is also expressed in fetal kidney, liver, and lung(8).
The human placenta and maternal decidua are rich sources of growth factors which are involved in the regulation of growth and development of the fetus, including IGF-I, IGF-II, basic fibroblast growth factor, TGF-α, TGF-β, NGF, and platelet-derived growth facor(9–14). IGF-I cord blood levels increase with increasing gestational age and are directly related to gestational age(15). It has been suggested that the effect of other polypeptide growth factors in fetal and placental development may be mediated in part through IGF-I and IGF-II(16).
The role of HGF in human fetal growth and development is not known. Prior studies of HGF in embryogenesis and placental development have focused generally on the expression of HGF mRNA in animal tissues(8, 16, 18), or alternatively, the effect of HGF on either fetal cell(19) or stem cell lines(20–22). Recently a “knockout” mouse with no HGF expression has been developed. HGF would appear to be essential for normal placental and liver development in utero(23, 24).
We hypothesized that HGF levels in cord blood would increase with increasing gestational age and also be related to fetal growth parameters. We therefore aimed to determine the levels of HGF in human umbilical vein sera and their correlates to late fetal growth and gestation.
METHODS
Umbilical venous serum was collected prospectively at 148 deliveries at the Women's and Children's Hospital. The following data were recorded at birth: birth weight and length, placental weight, pregnancy history, medications, alcohol consumption and smoking, perinatal events, mode of delivery, and use of anesthesia. Gestational age was determined from the date of the last menstrual period and/or early ultrasound examination, at 16-18 wk. Ballard scoring was performed at birth by a pediatrician if the first two parameters appeared to be at variance with the neonate's maturational status. Maternal venous, umbilical venous, and umbilical artery serum was collected at nine deliveries (two sets of twins).
Sera from 32 healthy adults who were hospital employees aged 25.1 ± 0.4 y and 54 healthy adolescents aged 13.9 ± 1.1 y and attending a suburban high school in Adelaide were also obtained prospectively. The study was approved by the Women's and Children's Hospital Human Ethics Committee.
Serum samples were stored at -20°C and measured within 6 wk. Serum HGF was measured by ELISA using rhHGF and anti-rhHGF mouse MAb (Institute of Immunology Co. Ltd., Tokyo, Japan). Microtiter plates were coated with anti-rhHGF mouse MAb. Test samples or standards diluted in FCS were added. After a further incubation, the wells were washed, and horseradish peroxidase-conjugated mouse MAb specific to HGF (but to a different epitope) was added. After a further incubation the enzyme substrate (sodium perborate, tetrahydrate) containing the color developer (o-phenylendiamine, dihydrochloride) was added. The reaction was stopped by adding 4N-sulfuric acid. Absorbance was measured at 492 nm in a microtiter plate reader (Dynatech, Guernsey, Channel Islands, UK). Standard curves using this method display linearity between 0.1 and 1.6 ng/mL. The assay has no cross-reactivity with plasmin, lipoprotein(a), IGF-I, IGF-II, epidermal growth factor, fibroblast growth factor, platelet-derived growth factor, and TGF-β. The intraassay and interassay coefficients of variation in our laboratory are 1.9 and 10.9%, respectively at 0.4 ng/mL, 4.3 and 11.3% at 0.8 ng/mL, and 2.1 and 12.5% at 1.6 ng/mL.
Serum IGF-I was measured after acid/ethanol extraction of serum by a double antibody RIA as previously described(25).
Statistical analysis. Variables that were not normally distributed (HGF) were log transformed before analysis. Comparison between groups was performed using unpaired t test. Relationships between cord HGF and dependent variables (gestational age, birth weight, birth length, and placental weight) were determined by linear, polynomial, and multiple stepwise regression analyses, using a Systat statistical program.
RESULTS
Of the total 148 pregnancies, 94 were normal; 25 of these were premature deliveries (i.e. less than 37 wk of gestation). There were 54 pregnancies complicated by medical conditions; 23 of these were premature deliveries. Gestational diabetes (n = 19), insulin-dependent diabetes (n = 19), pregnancy-induced hypertension (n = 12), acute viral hepatitis (n = 1), hepatocellular carcinoma(n = 1), acute pyelonephritis (n = 1), and chronic glomerulonephritis (n = 1) complicated these 54 pregnancies.
Cord HGF levels were more than 3-fold higher than HGF levels in adolescent(p < 0.0001) and adult (p < 0.0001) sera(Table 1). There was a significant relationship between gestational age and cord HGF in normal pregnancies (r = 0.42;p < 0.0001) (Fig. 1).
Within the normal pregnancy group, term neonates (37-42 wk of gestation,n = 69) had significantly higher cord HGF than preterm neonates(n = 25) [1.1 (0.78-1.45); 0.78 (0.46-1.03) ng/mL, respectively,p = 0.0007]. Correlations between cord HGF and birth weight(r = 0.23; p = 0.02), birth length (r = 0.23,p = 0.01), and placental weight (r = 0.22; p = 0.03) were not independent of gestational age. Furthermore, cord HGF did not differ between small for gestational age (less than 10th percentile for birth weight) and appropriate for gestational age (greater or equal to 10th percentile for birth weight) neonates at term. There was no relationship between cord HGF and cord IGF-I levels (n = 90). Cord IGF-I levels correlated with birth weight (r = 0.32, p = 0.003), birth length (r = 0.32, p = 0.002), and placental weight(r = 0.37, p = 0.001). These correlations were not independent of the significant relationship between IGF-I and gestational age(r = 0.82, p = 0.04).
Pregnancies complicated by medical conditions as detailed above had significantly higher cord HGF in premature deliveries compared with cord HGF in premature deliveries in normal pregnancies [0.92 (0.62-1.30), 0.69(0.41-1.0) ng/mL, respectively; p = 0.003]. There was no difference in cord HGF in term deliveries between normal and complicated pregnancies. Cord HGF levels in complicated pregnancies were not related to birth weight, birth length, or placental weight. There was no relationship between gestational age and cord HGF in pregnancies complicated by medical conditions, in contrast to normal pregnancies. No differences in cord HGF were observed between term and preterm neonates or between small for gestational age and appropriate for gestational age babies in complicated pregnancies. Cord HGF was not related to a history of smoking or alcohol consumption during pregnancy, mode of delivery, or use of anesthesia during labor in normal or complicated pregnancies.
Maternal venous serum HGF levels and simultaneous measurements of umbilical venous and arterial blood showed lower HGF levels in maternal serum than in the umbilical venous and arterial samples [0.56 (0.39-0.62) versus 0.68 (0.50-0.76) (p = 0.07) and 0.74 (0.47-0.89) ng/mL (p= 0.04), respectively. Umbilical venous and arterial samples were closely correlated (r = 0.825, p = 0.002, n = 11).
DISCUSSION
This study has examined HGF levels in umbilical vein sera for the first time and revealed several interesting findings. HGF levels are significantly higher in cord serum than in serum obtained from healthy adolescents and healthy adults. This is in contrast to serum IGF-I which peaks during puberty(26). There is an independent relationship between cord HGF and gestational age, but not with birth growth parameters, in normal pregnancies. However, this relationship is not seen in pregnancies complicated by medical conditions, predominantly diabetes and hypertension, with relatively higher cord HGF levels in these premature deliveries.
The higher levels of cord HGF in premature deliveries in complicated pregnancies could not be explained by one subset of medical conditions. One could speculate that there maybe a compensatory release of HGF from the placenta or fetal organs in these pregnancies secondary to intrauterine stress, but there was no inverse relationship between HGF and placental weight or birth weight to support this hypothesis. In support of the concept of compensatory release of HGF, mice homozygous for a targeted disruption of the HGF gene have severely impaired placenta development with a marked reduction in labyrinthine trophoblast cell numbers and consequently die in utero(23). A compensatory release of HGF by placental mesenchymal cells in a stressed placenta could help to preserve both placental function and weight.
Cord IGF-I levels in this study correlated with increasing birth size and gestational age. These observations have been made previously(15, 27) and act as further corroboration of the accuracy of gestational assessment. IGF-I levels tend to decrease with intrauterine growth retardation(15). IGF-I and HGF levels did not correlate making a direct effect of IGF-I on HGF release or action unlikely.
Previous evidence for HGF playing a role in human fetal growth and development is limited. Fetal rat liver, lung, and kidney express HGF(8), and HGF stimulates insulin production and islet cell cluster formation in cultured human fetal pancreatic cells, suggesting a role in islet development(28). The placenta is a rich source of HGF and immunohistochemical techniques demonstrate HGF in the placental mesenchyme and amniotic epithelium(7). The HGF receptor met is expressed by cytotrophoblasts(7).
Targeted disruption of the HGF gene in mice invariably results in death of the embryo due to a marked reduction of placental cytotrophoblastic cells(23, 24). Liver parenchymal mass is also markedly reduced with dissociated apoptotic liver parenchymal cells(24) and this defect may also render survival unlikely. These findings demonstrate that HGF is an essential factor for both placental growth and fetal organ growth and differentiation. Allelic disruption of the IGF-I gene results in profound growth retardation secondary to skeletal dwarfing and muscle hypoplasia(29, 30), but does not usually result in death.
HGF has no structural homologies with other known growth factors. It has the potential to act as a mitogen and motogen in vitro via direct interaction with its specific receptor encoded by the c-met oncogene(31). Its ability to induce endothelial cell motility in collagen gels by cell dissociation and migration, so called“scattering,” has been linked to angiogenesis and vascular repair(32). HGF stimulates directed and random migration of endothelial cells(5) and causes angiogenesis in vivo in the rabbit cornea(6). Met is strongly expressed by cells lining tubular structures(33). Renal epithelial cells form tubule like structures in vitro in response to HGF(20, 33, 34) and a similar response has been seen with lumen formation by human breast carcinoma cells and colon cancer cells(35). HGF antibodies inhibit the branching morphogenesis of the ureteric bud in primary organ culture(18). HGF stimulates the growth of fetal rat gastric and intestinal cells in vitro(19) and promotes the growth and differentiation of multipotent and erythroid hematopoietic progenitor cells(20, 22). HGF may also regulate primitive streak formation in the chick embryo(35). Therefore, there is accumulating evidence in vitro for the role of HGF in tissue morphogenesis. Our finding of a relationship between cord HGF and gestation rather than growth of the fetus and placenta in late normal pregnancy suggests that HGF may be a more significant factor in tissue and organ differentiation and development, than in linear fetal growth.
Abbreviations
- HGF:
-
hepatocyte growth factor
- TGF:
-
transforming growth factor
- NGF:
-
nerve growth factor
- rh:
-
recombinant human
References
Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, Tashiro K, Shimuzu S 1989 Molecular cloning and expression of human hepatocyte growth factor. Nature 342: 440–443.
Strain AJ 1993 Commentary: hepatocyte growth factor: another ubiquitous cytokine. J Endocrinol 137: 1–5.
Sonnenberg E, Meyer D, Weidner KM, Birchmeier C 1993 Scatter factor/hepatocyte growth factor and its receptor the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development. J Cell Biol 123: 223–235.
Rubin JS, Chan A M-L, Bottaro DP, Burgess WH, Taylor WG, Cech AC, Hirschfield DW, Wong J, Miki T, Finch PW, Aaronson SA 1991 A broad spectrum human lung fibroblast derived mitogen is a variant of hepatocyte growth factor. Proc Natl Acad Sci USA 88: 415–419.
Morimoto A, Okamura K, Hamanaka R, Sato Y, Shima N, Higashio K, Kuwano M 1991 Hepatocyte growth factor modulates migration and proliferation of human microvascular endothelial cells in culture. Biochem Biophys Res Commun 179: 1042–1049.
Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Olivero M, Naldini L, Gaudino G, Tamagnone L, Coffer A, Comoglio PM 1992 Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 119: 629–641.
Saito S, Sakakura S, Enomoto M, Ichijo M, Matsumoto K, Nakamura T 1995 Hepatocyte growth factor promotes the growth of cytotrophoblasts by a paracrine mechanism. J Biochem 117: 671–676.
Kagoshima M, Kinoshita T, Matsumoto K, Nakamura T 1992 Developmental changes in hepatocyte growth factor mRNA and its receptor in rat liver, kidney and lung. Eur J Biochem 210: 375–380.
Hill DJ, Clemmons DR, Riley SC, Bassett N, Challis JR 1993 Immunohistochemical localization of insulin-like growth factor (IGFs) and IGF binding proteins 1, 2 and 3 in human placenta and fetal membranes. Placenta 14: 1–12.
Hondermerck H, Courty J, Ledoux D, Blanckaert V, Barritault D, Boilly B 1990 Evidence of high and low affinity binding sites for basic fibroblast growth factor in mouse placenta. Biochem Biophys Res Commun 169: 272–281.
Han VK, D'Ercole AJ, Lee DC 1988 Expression of transforming growth factor alpha during development. Can J Physiol Pharmacol 66: 1113–1121.
Flanders KC, Cissel DS, Mullen LT, Danielpour D, Sporn MB, Roberts AB 1990 Antibodies to transforming growth factor-beta 2 peptides: specific detection of TGF-beta 2 in immunoassays. Growth Factors 3: 45–52.
Heinrich G, Meyer TE 1988 Nerve growth factor (NGF) is present in human placenta and semen, but undetectable in normal and Paget's disease blood: measurements with an anti-mouse NGF enzyme immunoassay using a recombinant human NGF reference. Biochem Biophys Res Commun 155: 482–486.
Jackson MR, Carney EW, Lye SJ, Ritchie JW 1994 Localization of two angiogenic growth factors (PDECGF and VEGF) in human placentae throughout gestation. Placenta 15: 341–353.
Lassarre C, Hardouin S, Daffos F, Forestier F, Frankenne F, Binoux M 1991 Serum insulin-like growth in the human fetus. Relationships with growth in normal subjects and in subjects with intrauterine growth retardation. Pediatr Res 29: 219–225.
Gluckman PD 1995 The endocrine regulation of fetal growth in late gestation: the role of insulin-like growth factors. J Clin Endocrinol Metab 86: 1047–1050.
Hu Z, Evarts RP, Fujio K, Marsden ER, Thorgeirsson S 1993 Expression of hepatocyte growth factor and c-met genes during hepatic differentiation and liver development in the rat. Am J Pathol 142: 1823–1830.
Wolf AS, Kolatsi-Joannou M, Hardman P, Andermarcher E, Moorby C, Fine LC, Jat PS, Noble MD, Gherardi E 1995 Roles of hepatocyte growth factor/scatter proof and the met receptor in the early development of the metanephros. J Cell Biol 128: 171–184.
Fukamachi H, Ichinose M, Tsukada S, Kakei N, Suzuki T, Miki K, Kurokawa K, Masui T 1994 Hepatocyte growth factor specifically stimulates gastrointestinal epithelial growth in primary culture. Biochem Biophys Res Commun 205: 1445–1451.
Mizuno K, Higuchi O, Ihle JN, Nakamura T 1993 Hepatocyte growth factor stimulates growth of hematopoietic progenitor cells. Biochem Biophys Res Commun 194: 178–186.
Suzuki M, Nakamura T, Ikeda M, Hayashi T, Kawaguchi Y, Sakai O 1994 Cloned cells develop renal cortical collecting tubules. Nephron 68: 118–124.
Galimi F, Bagnara GP, Bonsi L, Cottone E, Follenzi A, Simeone A, Comoglio PM 1994 Hepatocyte growth factor induces proliferation and differentiation of multipotent and erythroid hemopoietic progenitors. J Cell Biol 127: 1743–1754.
Uehara Y, Minowa O, Mori C, Shiota K, Kuno J, Noda T, Kitamura M 1995 Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature 373: 702–705.
Schmidt C, Bladt F, Goedecke S, Brinkmann V, Zschiesche W, Sharpe M, Gherardi E, Birchmeier C 1995 Scatter factor/hepatocyte growth factor is essential for liver development. Nature 373: 699–702.
Baxter RC, DeMellow JS, Burleigh BD 1987 Natural and recombinant DNA-derived human insulin-like growth factor-1 compared for use in radioligned assays. Clin Chem 33: 544–548.
Handelsman DJ, Spaliviero JA, Scott CO, Baxter RC 1987 Hormonal regulation of the peripubertal surge of insulin-like growth factor-1 in the rat. Endocrinology 120: 491–496.
Gluckman PD, Grumbach MM, Kaplan SL 1981 The neuroendocrine regulation and function of growth hormone and prolactin in the mammalian fetus. Endocr Rev 2: 363–395.
Otonkoski T, Beattie GM, Rubin JS, Lopez AD, Baird A, Hayek A 1994 Hepatocyte growth factor/scatter factor has insulinotropic activity in human fetal pancreatic cells. Diabetes 43: 947–953.
Liu J-P, Baker J, Robertson EJ, Efstratiadis A 1993 Mice carrying null mutations of the genes encoding insulin-like growth factor 1(IGF-1) and type 1 IGF receptor (IGF1r). Cell 75: 59–72.
Baker J, Liu J-P, Robertson EJ, Efstratiadis A 1993 Role of insulin-like growth factors in embryonic and postnatal growth. Cell 75: 73–82.
Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Van de Woude GF, Aaronson SA 1991 Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251: 802–804.
Rosen EM, Jaken S, Carley W, Luckett PM, Setter E, Bhargava M, Goldberg IM 1991 Regulation of motility in bovine brain endothelial cells. J Cell Physiol 146: 325–335.
Tsarfaty I, Resau JH, Rulong S, Keydar I, Faletto DL, Van de Woude GF 1992 The met proto-oncogene receptor and lumen formation. Science 257: 1258–1261.
Santos OFP, Moura LA, Rosen EM, Nigam SK 1993 Modulation of HGF-induced tubulogenesis and branching by multiple phosphorylation mechanisms. Dev Biol 159: 535–548.
Stern CD, Ireland GW, Herrick SE, Gherardi E, Gray J, Perryman M, Stoker M 1990 Epithelial scatter factor and development of the chick embryonic axis. Development 110: 1271–1284.
Acknowledgements
The authors thank Prof. John Boulton and Anthea Magarey for providing control sera, the staff of the Serology Department, Women's and Children's Hospital, Dr. M. Lewitt, Royal Prince Alfred Hospital, Sydney, for IGF analyses, and Julie Temby for expert secretarial assistance.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Khan, N., Couper, J., Goldsworthy, W. et al. Relationship of Hepatocyte Growth Factor in Human Umbilical Vein Serum to Gestational Age in Normal Pregnancies. Pediatr Res 39, 386–389 (1996). https://doi.org/10.1203/00006450-199603000-00002
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1203/00006450-199603000-00002